Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Leukemia & lymphoma Année : 2022

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Alex F. Herrera
  • Fonction : Auteur
Craig Y. Okada
  • Fonction : Auteur
Elizabeth H. Cull
  • Fonction : Auteur
Nancy L. Bartlett
  • Fonction : Auteur
Javier Briones
  • Fonction : Auteur
Ian Chau
  • Fonction : Auteur
Hailing Lu
  • Fonction : Auteur
Adam Yakovich
  • Fonction : Auteur
Michael Chen
  • Fonction : Auteur
Jan H. ter Meulen
  • Fonction : Auteur
Sergey Yurasov
  • Fonction : Auteur
Frank J. Hsu
  • Fonction : Auteur

Résumé

Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression. This open-label, multicenter, phase 1/2 trial evaluated the safety, tolerability, and preliminary efficacy of intratumoral G100 injections following localized low-dose radiation in patients with follicular lymphoma (ClinicalTrials.gov #NCT02501473). The study was comprised of a G100 dose escalation (5 or 10 mu g/dose, or 20 mu g/dose for large tumors); a randomized component comparing G100 to G100 plus pembrolizumab; and G100 20 mu g/dose expansion. Adverse events grade >= 3 were uncommon in patients treated with G100, and no unexpected toxicities were observed when combined with pembrolizumab. G100 20 mu g (n = 18) resulted in an overall response rate of 33.3% and abscopal tumor regression in 72.2% of patients. This early-phase study provides a foundation for combining an intratumoral TLR4 agonist with agents to produce immune-mediated responses in follicular lymphoma with limited added toxicity.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-03519467 , version 1 (10-01-2022)

Identifiants

Citer

Ahmad S. Halwani, Carlos Panizo, Iris Isufi, Alex F. Herrera, Craig Y. Okada, et al.. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩. ⟨hal-03519467⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More